Dendritic cell based vaccines for HIV infection: The way ahead

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 11, 2013, Pages 2445-2452

  García, Felipe ^a   Plana, Montserrat ^a   Climent, Nuria ^a   León, Agathe ^a   Gatell, Josep M ^a   Gallart, Teresa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Dendritic cells; Functional cure; HIV; T cell responses; Therapeutic vaccine

Indexed keywords

ADENOSINE DEAMINASE; DENDRITIC CELL VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; MESSENGER RNA;

ANTIGEN PRESENTATION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENZYME ASSAY; FEASIBILITY STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MYELOID DENDRITIC CELL; NONHUMAN; REVIEW; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS TRANSMISSION; DENDRITIC CELL; HIV INFECTIONS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; TREATMENT OUTCOME;

AIDS VACCINES; DENDRITIC CELLS; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 84887445284     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25876     Document Type: Review

References (73)

1. Palella FJJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al.; HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodefciency virus infection. N Engl J Med 1998; 338: 853-60; PMID: 9516219; http://dx.doi.org/10.1056/ NEJM199803263381301 (Pubitemid 28135961)
2. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confrm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9: 727-8; PMID: 12754504; http://dx.doi.org/10.1038/nm880 (Pubitemid 36749221)
3. Sidibé M. Newsmaker interview: Michel Sidibé. New HIV infections drop, but treatment demands rise. Interview by Jon Cohen. Science 2010; 330: 1301; PMID: 21127221; http://dx.doi.org/10.1126/science.330.6009.1301
4. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 2004; 305: 205-8; PMID: 15247470; http://dx.doi.org/10.112 6/science.1100 60 0 (Pubitemid 38886726)
5. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen, an immunologic modifer, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. JAMA 2000; 284: 2193-202; PMID: 11056590; http://dx.doi.org/10.1001/jama.284.17.2193
6. Gorse GJ, Simionescu RE, Patel GB. Cellular immune responses in asymptomatic human immunodefciency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1. Clin Vaccine Immunol 2006; 13: 26-32; PMID: 16425996; http://dx.doi.org/10.1128/CVI.13.1.26- 32.2006
7. Dorrell L, Yang H, Iversen AK, Conlon C, Suttill A, Lancaster M, et al. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 2005; 19: 1321-3; PMID: 16052088; http://dx.doi.org/10.1097/ 01.aids.0000180104.65640.16 (Pubitemid 41224902)
8. García F, León A, Gatell JM, Plana M, Gallart T. Therapeutic vaccines against HIV infection. Hum Vaccin Immunother 2012; 8: 569-81; PMID: 22634436; http://dx.doi.org/10.4161/hv.19555
9. Ga rcía F, R out y JP. Cha llenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 2011; 29: 6454-63; PMID: 21791232; http://dx.doi.org/10.1016/j.vaccine.2011.07.043
10. Papagno L, Alter G, Assoumou L, Murphy RL, Garcia F, Clotet B, et al.; ORVACS Study Group. Comprehensive analysis of virus-specifc T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011; 25: 27-36; PMID: 21076273; http://dx.doi.org/10.1097/QAD.0b013e328340fe55
11. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 1998 Mar 19;392: 245-252. (Pubitemid 28155090)
12. Wu L, KewalRamani VN. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol 2006; 6: 859-68; PMID: 17063186; http://dx.doi.org/10.1038/nri1960 (Pubitemid 44631654)
13. Izquierdo-Useros N, Naranjo-Gómez M, Archer J, Hatch SC, Erkizia I, Blanco J, et al. Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood 2009; 113: 2732-41; PMID: 18945959; http://dx.doi.org/10.1182/blood-2008-05-158642
14. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 2002; 17: 211-20; PMID: 12196292; http://dx.doi.org/10.1016/S1074-7613(02)00365-5 (Pubitemid 35245963)
15. Lubong Sabado R, Kavanagh DG, Kaufmann DE, Fru K, Babcock E, Rosenberg E, et al. In vitro priming recapitulates in vivo HIV-1 specifc T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection. PLoS One 2009; 4:e4256; PMID: 19165342; http://dx.doi.org/10.1371/journal. pone.0004256
16. Climent N, Martinez-Navio JM, Gil C, Garcia F, Rovira C, Hurtado C, et al. Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV. Immunol Cell Biol 2009; 87: 634-9; PMID: 196 68260; http://dx.doi.org/10.1038/icb.2009.53
17. Pacheco R, Martinez-Navio JM, Lejeune M, Climent N, Oliva H, Gatell JM, et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci U S A 2005; 102: 9583-8; PMID: 15983379; http://dx.doi.org/10.1073/pnas.0501050102 (Pubitemid 40981724)
18. Martinez-Navio JM, Casanova V, Pacheco R, Naval-Macabuhay I, Climent N, Garcia F, et al. Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. J Leukoc Biol 2011; 89: 127-36; PMID: 20959412; http://dx.doi.org/10.1189/jlb.1009696
19. Martinez-Navio JM, Climent N, Pacheco R, Garcia F, Plana M, Nomdedeu M, et al. Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation. Immunology 2009; 128: 393-404; PMID: 20067539; http://d x. d oi. o r g/10.1111/j.13 65-2 5 67. 2 0 0 9. 0 31 21. x
20. Mangeat B, Tu r e l l i P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424: 99-103; PMID: 12808466; http://dx.doi.org/10.1038/nature01709 (Pubitemid 36834849)
21. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005; 435: 108-14; PMID: 15829920; http://dx.doi.org/10.1038/nature03493 (Pubitemid 40655917)
22. Pion M, Granelli-Piperno A, Mangeat B, Stalder R, Correa R, Steinman RM, et al. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J Exp Med 2006; 203: 2887-93; PMID: 17145955; http://dx.doi.org/10.1084/jem.20061519 (Pubitemid 46026166)
23. Rodríguez-García M, Oliva H, Climent N, García F, Gatell JM, Gallart T. Human immature monocyte-derived dendritic cells produce and secrete alpha-defensins 1-3. J Leukoc Biol 2007; 82: 1143-6; PMID: 17684038; http://dx.doi.org/10.1189/jlb.0507295 (Pubitemid 350133510)
24. Rodríguez-García M, Oliva H, Climent N, Escribese MM, García F, Moran TM, et al. Impact of alpha-defensins1-3 on the maturation and differentiation of human monocyte-derived DCs. Concentration-dependent opposite dual effects. Clin Immunol 2009; 131: 374-84; PMID: 19237318; http://dx.doi.org/10.1016/j.clim.2009.01.012
25. Rodríguez-García M, Climent N, Oliva H, Casanova V, Franco R, Leon A, et al. Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression. PLoS One 2010; 5:e9436; PMID: 20195543; http://dx.doi.org/10.1371/journal. pone.0009436
26. Letvin NL, Wa lker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 2003; 9: 861-6; PMID: 12835706; http://dx.doi.org/10.1038/ nm0703-861 (Pubitemid 36889927)
27. Day CL, Wa l k e r BD. Progress in defning CD4 helper cell responses in chronic viral infections. J Exp Med 2003; 198: 1773-7; PMID: 14676292; http://dx.doi.org/10.1084/jem.20031947 (Pubitemid 38032110)
28. Kaech SM, Ahmed R. Immunology. CD8 T cells remember with a little help. Science 2003; 300: 263-5; PMID: 12690179; http://dx.doi.org/10.1126/science. 1084511 (Pubitemid 36433703)
29. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine effcacy. J Clin Invest 2002; 109: 1519-26; PMID: 12070296 (Pubitemid 34663511)
30. Goulder PJ, Brander C, Ta n g Y, Tremblay C, Colbert RA, Addo MM, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412: 334-8; PMID: 1146 016 4; http://dx.doi.org/10.1038/35085576 (Pubitemid 32694384)
31. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'sullivan KM, et al. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodefciency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005; 79: 13239-49; PMID: 16227247; http://dx.doi.org/10.1128/JVI.79.21.13239-13249.2005 (Pubitemid 41508139)
32. Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, et al. De novo generation of escape variant-specifc CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodefciency virus type 1 infection. J Virol 2005; 79: 12952-60; PMID: 16188997; http://dx.doi.org/10. 1128/JVI.79.20.12952-12960.2005 (Pubitemid 41433214)
33. Feeney ME, Ta n g Y, Pfafferott K, Roosevelt KA, Draenert R, Troc ha A, et al. HIV-1 viral escape in infancy followed by emergence of a variant-specifc CTL response. J Immunol 2005; 174: 7524-30; PMID: 15944251 (Pubitemid 40806255)
34. Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood 2003; 101: 4505-11; PMID: 12576311; http://dx.doi.org/10.1182/blood-2002-10-3189 (Pubitemid 36857821)
35. Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, Jerandi G, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002; 168: 4796-801; PMID: 119 7 10 31 (Pubitemid 34441389)
36. Sallusto F, Lanzavecchia A. Effcient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-18; PMID: 8145033; http://dx.doi.org/ 10.1084/jem.179.4.1109
37. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811; PMID: 10837075; http://dx.doi.org/10.1146/annurev.immunol.18.1.767 (Pubitemid 30365397)
38. Larsson M, Fonteneau JF, Bhardwaj N. Cross-presentation of cell-associated antigens by dendritic cells. Curr Top Microbiol Immunol 2003; 276: 261-75; PMID: 12797452; http://dx.doi.org/10.1007/978-3-662-06508-2-12 (Pubitemid 36538356)
39. Lapenta C, Santini SM, Logozzi M, Spada M, Andreotti M, Di Pucchio T, et al. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 2003; 198: 361-7; PMID: 12 8 74 2 6 6; http://dx.doi.org/10.1084/jem.20 021924 (Pubitemid 36987861)
40. Yoshida A, Tanaka R, Murakami T, Takahashi Y, Koyanagi Y, Nakamura M, et al. Induction of protective immune responses against R5 human immunodefciency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: possible involvement of a novel factor of human CD4(+) T-cell origin. J Virol 2003; 77: 8719-28; PMID: 12885891; http://dx.doi.org/10.1128/JVI.77.16.8719-8728.2003 (Pubitemid 36936083)
41. Aline F, Brand D, Bout D, Pierre J, Fouquenet D, Verrier B, et al. Generation of specifc Th1 and CD8+ T-cell responses by immunization with mouse CD8+ dendritic cells loaded with HIV-1 viral lysate or envelope glycoproteins. Microbes Infect 2007; 9: 536-43; PMID: 1735 0307; http://dx.doi.org/10.1016/j. micinf.2007.01.021 (Pubitemid 46442796)
42. Lu W, Wu X, Lu Y, Guo W, Andrieu JM. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003; 9: 27-32; PMID: 12496959; http://dx.doi.org/10. 1038/nm806 (Pubitemid 36098256)
43. Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998; 14: 551-60; PMID: 9591709; http://dx.doi.org/10.1089/aid.1998.14.551 (Pubitemid 28196782)
44. Lu W, Arraes LC, Ferreira W T, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10: 1359-65; PMID: 15568033; http://dx.doi.org/10.1038/nm1147 (Pubitemid 40022718)
45. García F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, et al. Therapeutic immunization with dendritic cells loaded with inactivated autologous HIV-1 in chronic HIV-1 infected patients. J Infect Dis 2005; 191: 1680-5; http://dx.doi.org/10.1086/429340 (Pubitemid 40656756)
46. Ide F, Nakamura T, To m i z a w a M, Kawana-Tachikawa A, Odawara T, Hosoya N, et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol 2006; 78: 711-8; PMID: 16628588; http://dx.doi.org/10.1002/jmv.20612
47. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. Therapeutic immunization with human immunodefciency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008; 15: 284-92; PMID: 17942609; http://dx.doi.org/10.1128/CVI.00221-07 (Pubitemid 352025534)
48. Gandhi RT, O'Neill D, Bosch RJ, Chan ES, Bucy R P, Shopis J, et al.; AIDS Clinical Trials Group A5130 tea m. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vacci ne 2009; 27: 6088-94; PMID: 19 45 0 6 47; http://dx.doi.org/10.1016/j. vaccine.2009.05.016
49. Kloverpris H, Karlsson I, Bonde J, Thorn M, Vinner L, Pedersen AE, et al. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009; 23: 1329-40; PMID: 19528789; http://dx.doi.org/10.1097/QAD. 0b013e32832d9b00
50. Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C, Healey D, Jain R, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010; 134: 140-7; PMID: 198 895 8 2; http://dx.doi.org/10.1016/j. clim.2009.09.009
51. García F, Climent N, Assoumou L, Gil C, González N, Alcamí J, et al.; DCV2/MANON07- AIDS Vaccine Research Objective Study Group. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011; 203: 473-8; PMID: 21233310; http://dx.doi.org/10.1093/infdis/jiq077
52. Routy JP, Angel J, Ve zina S, Tremblay C, Loutfy M, Gill J, et al. Final Analysis of a Phase 2 Study of an Autologous DC Immunotherapy (AGS-004) Showed Positive Outcomes in Primary Endpoint of Viral Load Control, and Favorable Safety and Immunogenicity Profle, in Subjects Undergoing Structured Treatment Interruption of ART (Abstract 385). 18th Conference on Retroviruses and Opportunistic Infections Boston February 27-March 2 2011.
53. Va n Gu lc k E, Vlieghe E, Vekema ns M, Van Tendeloo VF, Van De Velde A, Smits E, et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 2012; 26:F1-12; PMID: 22156965; http://dx.doi.org/10.1097/QAD.0b013e32834f33e8
54. Allard SD, De Keersmaecker B, de Goede AL, Ve r s c h u re n EJ, Koetsveld J, Reedijk ML, et al. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin Immunol 2012; 142: 252-68; PMID: 22177848; http://dx.doi.org/10.1016/j.clim.2011.10.010
55. Garcia F, Climent N, Guardo AC, Gil C, Leon A, Autran B, et al. A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. Sci Transl Med 2013; 5: 166ra2.
56. Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C, Healey D, Jain R, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010; 134: 140-7; PMID: 19 8 89 582; http://dx.doi.org/10.1016/j. clim.2009.09.009
57. Routy JP, Boulassel MR, Mona L, Sylvie V, Cecile T, Jonathan A, et al. Safety and viral load changes in HIV-1 infected subjects treated with autologous dendritic immune therapy following ART discontinuation (CTN#239) Abstract OA04-05. AIDS Vaccine 2009 Conference Paris, France from 19 - 22 October 2009.
58. Climent N, Guerra S, García F, Rovira C, Miralles L, Gómez CE, et al. Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specifc CD8(+) T cell responses in HIV-1-infected individuals. PLoS One 2011; 6:e19644; PMID: 21625608; http://dx.doi.org/10.1371/journal. pone.0019644
59. Pion M, Serramia MJ, Diaz L, Bryszewska M, Gallart T, García F, et al. Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer. Biomaterials 2010; 31: 8749-58; PMID: 2 0832111; http://dx.doi.org/10.1016/j.biomaterials.2010.07.093
60. Climent N, Munier S, Piqué N, García F, Pavot V, Leon A, et al. Loading dendritic cells from HIV-1 infected patients with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specifc T cell response. AIDS Vaccine 2012 Conference Boston, USA September 9-12, 2012.
61. Aline F, Brand D, Pierre J, Roingeard P, Séverine M, Verrier B, et al. Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 2009; 27: 5284-91; PMID: 19450633; http://dx.doi.org/10.1016/j.vaccine.2009.05.028
62. Guillon C, Mayol K, Terrat C, Compagnon C, Primard C, Charles MH, et al. Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine 2007; 25: 7491-501; PMID: 17904700; http://dx.doi.org/10.1016/ j.vaccine.2007.08.060 (Pubitemid 47516619)
63. Casanova V, Naval-Macabuhay I, Massanella M, Rodríguez- García M, Blanco J, Gatell JM, et al. Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals. PLoS One 2012; 7:e51287; PMID: 23240012; http://dx.doi.org/10.1371/ journal.pone.0051287
64. Blanco J, Va lenzuela A, Herrera C, Lluís C, Hovanessian AG, Franco R. The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression. FEBS Lett 2000; 477: 123-8; PMID: 10899322; http://dx.doi.org/10.1016/S0014-5793(00)01751-8 (Pubitemid 30438869)
65. Brahmer JR, Ty k o d i SS, Chow LQ, Hwu WJ, To p a l i a n SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65; PMID: 22658128; http://dx.doi.org/10.1056/ NEJMoa1200694
66. To p a l i a n SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54; PMID: 22658127; http://dx.doi.org/10. 1056/NEJMoa1200690
67. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, et al. Enhancing SIV-specifc immunity in vivo by PD-1 blockade. Nature 2009; 458: 206-10; PMID: 19078956; http://dx.doi.org/10.1038/nature07662
68. Va n Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012; 72: 1661-71; PMID: 22337996; http://dx.doi.org/10.1158/0008- 5472.CAN-11-2957
69. Brentjens RJ, Davila ML, Riviere I, Park J, Wa ng X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 77ra 38; PMID: 2 3515 0 8 0; http://dx.doi.org/10.1126/scitranslmed.3005930
70. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al.; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-20; PMID: 19843557; http://dx.doi.org/10.1056/NEJMoa0908492
71. Sandström E, Nilsson C, Hejdeman B, Bråve A, Bratt G, Robb M, et al.; HIV Immunogenicity Study 01/02 Team. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modifed vaccinia virus Ankara. J Infect Dis 2008; 198: 1482-90; PMID: 18808335; http://dx.doi.org/10.1086/592507
72. Flamar A, Le Grand R, Contreras V, Zurawski S, Dereudre-Bosquet N. M, et al. Targeting HIV Gag p24 To DICR On Dendritic Cells Induces T Cell And Potent And Long-Lasting Antibody Responses In Non-Human Primates. AIDS Vaccine Conference Boston, USA September 9-12, 2012.
73. Flynn BJ, Kastenmüller K, Wille-Reece U, Tomaras GD, Alam M, Lindsay RW, et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A 2 011; 108: 7131-6; PMID: 21467219; http://dx.doi.org/10.1073/pnas.1103869108